The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C09 | Agents acting on the renin-angiotensin system | |
| 3 | C09A | ACE inhibitors, plain | |
| 4 | C09AA | ACE inhibitors, plain | |
| 5 | C09AA02 | Enalapril |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 10 mg |
| PAREN - Parenteral | 10 mg |
| Active Ingredient | Description | |
|---|---|---|
| Enalapril |
Enalapril is hydrolysed via hepatic CES 1 to the active metabolite enalaprilat, which acts as an ACE inhibitor. ACE is a peptidyl dipeptidase which catalyses the conversion of angiotensin I to the vasoconstrictor substance angiotensin II and hence inhibition of ACE results in decreased plasma angiotensin II. This also leads to increased plasma renin activity and decreased aldosterone secretion. The mechanism of action of enalapril is therefore primarily via the suppression of the RAAS. However, ACE is identical to kininase II, and so enalapril may also exert its effects by blocking the degradation of bradykinin, a potent vasodepressor peptide. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ALAPREN Tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| AQUMELDI Orodispersible tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ENAP Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| INNOVACE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| KORANDIL Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| RENITEC Tablet | Pharmaceutical Benefits Scheme (AU) | MPI, Generic | |
| VASOTEC Tablet | FDA, National Drug Code (US) | MPI, US: SPL/Old |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
